利司那肽治疗2型糖尿病合并肝硬化的疗效及对患者血糖、肝脏硬度的影响

Efficacy of lixisenatide in the treatment of type 2 diabetes mellitus complicated with liver cirrhosis and its influence on blood glucose and liver stiffness

目的探讨利司那肽治疗2型糖尿病合并肝硬化的疗效及对患者血糖、肝脏硬度的影响。方法64例2型糖尿病合并肝硬化患者,以数字盲选法分为常规组与观察组,每组32例。常规组给予胰岛素泵治疗,观察组给予胰岛素泵联合利司那肽治疗。对比两组患者的治疗效果,治疗前后的糖代谢指标[空腹血糖(FPG)、餐后2 h血糖(2 h PG)及糖化血红蛋白(HbA1c)]及肝脏硬度。结果观察组患者的总有效率93.8%高于常规组的75.0%,差异具有统计学意义(P<0.05)。治疗后,两组患者的FPG、2 h PG、HbA1c水平均低于治疗前,且观察组患者的FPG、2 h PG、HbA1c水平分别为(6.40±1.07)mmol/L、(9.04±1.41)mmol/L、(6.36±1.04)%,低于常规组的(7.28±1.32)mmol/L、(10.14±1.72)mmol/L、(7.23±1.25)%,差异具有统计学意义(P<0.05)。治疗后,两组患者的肝脏硬度均低于治疗前,且观察组患者的肝脏硬度(7.0±0.9)kPa低于常规组的(9.4±1.2)kPa,差异具有统计学意义(P<0.05)。结论利司那肽可有效改善2型糖尿病合并肝硬化患者的血糖水平,在提升临床疗效的同时,还能降低患者的肝脏硬度,对改善预后有着积极意义,值得深入研究与推广。

Objective To discuss the efficacy of lixisenatide in the treatment of type 2 diabetes mellitus complicated with liver cirrhosis and its influence on blood glucose and liver stiffness.Methods A total of 64 patients with type 2 diabetes mellitus and liver cirrhosis were divided into conventional group and observation group by digital blind selection,with 32 cases in each group.The conventional group was treated with insulin pump,while the observation group treated with insulin pump combined with lixisenatide.Both groups were compared in terms of therapeutic effects,glucose metabolism indexes[fasting plasma glucose(FPG),2 h postprandial glucose(2 h PG)and glycosylated hemoglobin(HbA1c)]and liver stiffness before and after treatment.Results The total effective rate of the observation group was 93.8%higher than 75.0%of the conventional group,and the difference was statistically significant(P<0.05).After treatment,the levels of FPG,2 h PG and HbA1c in the two groups were lower than those before treatment in this group;the levels of FPG,2 h PG and HbA1c in the observation group were(6.40±1.07)mmol/L,(9.04±1.41)mmol/L,and(6.36±1.04)%,which were lower than(7.28±1.32)mmol/L,(10.14±1.72)mmol/L,and(7.23±1.25)%in the conventional group;all the differences were statistically significant(P<0.05).After treatment,the liver stiffness of the two groups was lower than that of this group before treatment,and the liver stiffness(7.0±0.9)kPa of the observation group was lower than(9.4±1.2)kPa of the conventional group.All the differences were statistically significant(P<0.05).Conclusion Lixisenatide can effectively improve the blood glucose level of patients with type 2 diabetes mellitus and liver cirrhosis,enhance clinical efficacy and at the same time reduce the liver stiffness of patients,which is of positive significance to improve the prognosis and is worthy of in-depth study and promotion.